Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

FDA Approves First-Line Ofatumumab for Fludarabine-Ineligible Patients With CLL

April 17th 2014

The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.

Dr. Salerno on Access to Care for Breast Cancer Patients

April 17th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses access to care for patients with breast cancer.

Dr. Penson on Advantages/ Disadvantages of Large Urologic Practices

April 17th 2014

David F. Penson, MD, MPH, director, Center for Surgical Quality and Outcomes Research Professor of Urologic Surgery, Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology, professor of medicine, Vanderbilt University Medical Center, discusses some of the advantages and disadvantages of a large urologic practice.

Oncologist Compensation Highest in Southwest, With 23% in ACOs Already

April 16th 2014

Among physicians, oncologists fall slightly above the middle in terms of compensation, with average earnings reported at $290,000.

As CMS Contemplates ICD-10 Delay, Take Advantage of the Slow Rollout

April 15th 2014

Even as the Centers for Medicare & Medicaid Services (CMS) examines the implications of the ICD-10 delay there are some steps oncology and hematology practice managers can take now before the rollout gets into full swing.

Small Oncology Practices Can Look to SHOP Marketplace for Employee Benefit Plans

April 14th 2014

Small oncology practices employing fewer than 50 full-time employees might consider looking to the Small Business Health Options Program offered through the Affordable Care Act.

Reimbursement Models Force Oncologists to Balance Clinical and Financial Risk

April 11th 2014

I would like to begin by expressing my excitement about my new position as editor-in-chief of Oncology Business Management.

Delayed Launch of Sunshine Act Website May Affect Physician Review

April 10th 2014

A delay in the launch of the Centers for Medicare & Medicaid Services (CMS) web site that tracks the financial relationship between physician and industry may prevent physicians from fully reviewing the data.

Medicare Data Reveals Top Billing Docs

April 9th 2014

Buckling to calls for transparency and a Wall Street Journal court case requiring the agency to provide public access to physician billing records, the Centers for Medicare & Medicaid Services (CMS) released a database containing transactions worth $77 billion by 880,000 physicians and physician practices certified to collect from Medicare

MSK's CAR Trials Halted Temporarily Amid Safety Review

April 9th 2014

Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia

Avoiding Meaningful Use Fee Adjustments

April 8th 2014

Community oncologists and hematologists who participate in the Medicare Electronic Health Records Incentive Program may be subject to fee adjustments from the agency beginning January 1, 2015.

Aduro BioTech Immunotherapy Duo Shows Promise in Pancreatic Cancer

April 3rd 2014

The use of immunotherapy for pancreatic cancer has had limited exposure, but Aduro BioTech, Inc, has had phase II success with an approach in which two vaccines are administered. The vaccines, GVAX Pancreas and CRS-207, are administered to patients sequentially.

The Retreatment Question: Research Suggests Benefits to Continuing Molecularly Targeted Therapy Beyond Progression

April 2nd 2014

The readministration of a cytotoxic antineoplastic agent is a well-established management paradigm in a number of malignancies, yet it is generally believed such a strategy may not prove beneficial if the patient experiences disease progression while receiving the therapy.

Now That ICD-10 Is Delayed, Too, What Should Providers Do?

April 2nd 2014

While the sustainable growth rate (SGR) debate has been put off for 2014, what should physicians be looking to as the transition to ICD-10 has been delayed for the second time in two years?

A Look at I-SPY 2: Novel Trial Design May Expand the Scope of Oncology Drug Development

April 2nd 2014

Amid a growing recognition of the need to improve the process of developing oncology drugs, the novel I-SPY 2 clinical trial in breast cancer has demonstrated the potential to deliver new, effective treatment options more rapidly to patients who would most benefit while dramatically reducing the time and costs currently required to evaluate experimental therapies.

GAO Report Says Challenges Continue for Information Exchange Initiatives

April 1st 2014

Providers cited issues related to insufficient standards, concerns about how privacy rules can vary among states, difficulties in matching patients to their records, and costs associated with exchange

Temporary SGR Patch Expected to Clear Senate Vote

March 31st 2014

The Senate is expected to consider and vote on a bill passed by the House on March 27 that includes language to patch the sustainable growth rate (SGR) formula for 12 months and delay ICD-10 implementation until at least October 1, 2015

Should Your Practice Join a Provider-Based Research Network: March 31, 2014

March 31st 2014

Provider-based research networks (PBRNs) make clinical trials available to community-based practices.

FDA Panel Unanimously Recommends New DNA Stool Test

March 27th 2014

The FDA's Molecular and Clinical Genetics advisory committee has unanimously supported the safety, efficacy, and positive risk-benefit profile of the noninvasive stool-based DNA test Cologuard in a 10-0 vote.

US House Repeals SGR Formula, Senate Vote Looming

March 27th 2014

It looks like trouble continues for a bill that would delay payment cuts to physicians who treat Medicare patients for one year